TY - JOUR
T1 - Endothelin receptor antagonist attenuates inflammatory response and prolongs the survival time in a neonatal sepsis model
AU - Goto, Tatenobu
AU - Hussein, Mohamed Hamed
AU - Kato, Shin
AU - Daoud, Ghada Abdel Hamid
AU - Kato, Takenori
AU - Kakita, Hiroki
AU - Mizuno, Haruo
AU - Imai, Masaki
AU - Ito, Tetsuya
AU - Kato, Ineko
AU - Suzuki, Satoshi
AU - Okada, Noriko
AU - Togari, Hajime
AU - Okada, Hidechika
PY - 2010/12
Y1 - 2010/12
N2 - Purpose: To evaluate effects of endothelin receptor antagonist ETR-P1/fl in a neonatal sepsis model. Method: Eighteen anesthetized and mechanically ventilated 3-day-old piglets were divided into three groups. Six piglets received cecal ligation and perforation (CLP group). Six piglets were administrated a continuous infusion of ETR-P1/fl (0.05 mg/kg/h), an antisense homology box-derived peptide with an endothelin A receptor antagonist effect, starting 30 min after CLP (ETR-P1/fl group). Six piglets acted as the sham group. Mean arterial pressure (MAP), heart rate, cardiac output, arterial blood gas, body temp (BT), serum nitrite and nitrate (NOx), tumor necrosis factor (TNF)-α, and high-mobility group box 1 (HMGB-1) were measured before CLP and at 1, 3, 6, and 9 h after CLP. Results: Cecal ligation and perforation exposure evoked a state of shock and showed deteriorated cardiac output, pulmonary hypertension, decreased MAP, low oxygen saturation, and base excess (BE) with elevated TNF-α, NOx, and HMGB1. ETR-P1/fl administration resulted in higher MAP at 6 and 9 h after CLP, less negative BE, lower mean pulmonary arterial pressure (mPAP)/MAP ratio at 9 h after CLP, and lower TNF-α, NOx, and HMGB-1 compared to the CLP group. BT showed no differences between the groups. Survival time in the ETR-P1/fl group was longer than in the CLP group (18.9 ± 2.3 h vs. 9.0 ± 0.8 h, p < 0.01). Conclusions: ETR-P1/fl treatment significantly attenuated the elevation of NOx, TNF-α, and HMGB-1, which improved the systemic hypotension, pulmonary hypertension, and blood gases, thereby causing improvement of survival time in a progressive neonatal sepsis CLP model.
AB - Purpose: To evaluate effects of endothelin receptor antagonist ETR-P1/fl in a neonatal sepsis model. Method: Eighteen anesthetized and mechanically ventilated 3-day-old piglets were divided into three groups. Six piglets received cecal ligation and perforation (CLP group). Six piglets were administrated a continuous infusion of ETR-P1/fl (0.05 mg/kg/h), an antisense homology box-derived peptide with an endothelin A receptor antagonist effect, starting 30 min after CLP (ETR-P1/fl group). Six piglets acted as the sham group. Mean arterial pressure (MAP), heart rate, cardiac output, arterial blood gas, body temp (BT), serum nitrite and nitrate (NOx), tumor necrosis factor (TNF)-α, and high-mobility group box 1 (HMGB-1) were measured before CLP and at 1, 3, 6, and 9 h after CLP. Results: Cecal ligation and perforation exposure evoked a state of shock and showed deteriorated cardiac output, pulmonary hypertension, decreased MAP, low oxygen saturation, and base excess (BE) with elevated TNF-α, NOx, and HMGB1. ETR-P1/fl administration resulted in higher MAP at 6 and 9 h after CLP, less negative BE, lower mean pulmonary arterial pressure (mPAP)/MAP ratio at 9 h after CLP, and lower TNF-α, NOx, and HMGB-1 compared to the CLP group. BT showed no differences between the groups. Survival time in the ETR-P1/fl group was longer than in the CLP group (18.9 ± 2.3 h vs. 9.0 ± 0.8 h, p < 0.01). Conclusions: ETR-P1/fl treatment significantly attenuated the elevation of NOx, TNF-α, and HMGB-1, which improved the systemic hypotension, pulmonary hypertension, and blood gases, thereby causing improvement of survival time in a progressive neonatal sepsis CLP model.
KW - Antisense homology box-derived peptide
KW - Cytokines
KW - Newborn
KW - Nitric oxide
KW - Septic shock
UR - http://www.scopus.com/inward/record.url?scp=78649324710&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649324710&partnerID=8YFLogxK
U2 - 10.1007/s00134-010-2040-0
DO - 10.1007/s00134-010-2040-0
M3 - Article
C2 - 20845025
AN - SCOPUS:78649324710
SN - 0342-4642
VL - 36
SP - 2132
EP - 2139
JO - Intensive Care Medicine
JF - Intensive Care Medicine
IS - 12
ER -